Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Operating Income Loss of -$20.20 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +34.4% in Operating Income Loss from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$13.3 thousand | Q3 2018: -$2.3 thousand | Q4 2018: -$79.1 thousand | Q2 2019: -$71.1 thousand | Q3 2019: -$94.1 thousand | Q4 2019: -$166.0 thousand | Q1 2020: -$618.3 thousand | Q2 2020: -$264.9 thousand | Q2 2020: -$777.4 thousand | Q3 2020: -$525.9 thousand | Q3 2020: -$512.3 thousand | Q4 2020: -$352.0 thousand | Q1 2021: -$1.87 million | Q2 2021: -$1.79 million | Q3 2021: -$2.48 million | Q1 2022: -$7.45 million | Q2 2022: -$5.52 million | Q3 2022: -$5.50 million | Q1 2023: -$6.98 million | Q2 2023: -$11.34 million | Q3 2023: -$11.56 million | Q1 2024: -$7.92 million | Q2 2024: -$8.13 million | Q3 2024: -$8.46 million | Q1 2025: -$6.54 million | Q2 2025: -$6.07 million | Q3 2025: -$4.03 million.
- Over the full 10 years of available data (2019 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Operating Income Loss has declined by 13,120.9%.
- Historical annual values: Fiscal year 2025: -$20.20 million | Fiscal year 2024: -$30.80 million | Fiscal year 2023: -$39.50 million | Fiscal year 2022: -$28.23 million | Fiscal year 2021: -$10.10 million | Fiscal year 2021: -$10.10 million | Fiscal year 2020: -$2.43 million | Fiscal year 2020: -$724.7 thousand | Fiscal year 2019: -$376.9 thousand | Fiscal year 2019: -$152.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: